-
Product Insights
Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2023’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Respiratory Syncytial Virus Clinical Trials Overview The report provides an overview of the Respiratory Syncytial Virus (RSV) clinical trial scenario and top-line data relating to the clinical trials on it. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. Key Regions ·       Asia-Pacific ·       Europe ·       North...
-
Sector Analysis
Respiratory Syncytial Virus (RSV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
RSV Marketed and Pipeline Drugs Report Overview The respiratory syncytial virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold and later from infants suffering from respiratory disease. The most common clinical scenario for RSV is an upper respiratory tract infection that is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization occurring at ages two...